Olmesartan medoxomil (OLM) plus amlodipine (AML) improves BP goal attainment in moderate-to-severe hypertensive patients not adequately controlled with AML monotherapy

被引：0
|
作者：
Volpe, M. [1 ]
Laeis, P. [2 ]
Ammentorp, B. [2 ]
Haag, U. [3 ]
机构：
[1] Univ Rome, Div Cardiol, Rome, Italy
[2] Daiichi Sankyo Europe GmbH, Munich, Germany
[3] HaaPACS GmbH, Schriesheim, Germany
来源：
JOURNAL OF HYPERTENSION | 2008年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S473 / S473
页数：1
相关论文
共 36 条
  • [31] Blood pressure (BP)-lowering efficacy of olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) and benazepril (BN) plus amlodipine (AML) in patients (Pts) with type 2 diabetes mellitus (T2DM)
    Kereiakes, D.
    Neutel, J.
    Xu, J.
    Lipka, L.
    Chavanu, K.
    Dubiel, R.
    JOURNAL OF HYPERTENSION, 2008, 26 : S455 - S455
  • [32] Efficacy and Safety of a Stepped-Care Regimen Using Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension An Open-Label, Long-Term Study
    Volpe, Massimo
    Miele, Cristina
    Haag, Uwe
    CLINICAL DRUG INVESTIGATION, 2009, 29 (06) : 381 - 391
  • [33] Efficacy and Safety of a Stepped-Care Regimen Using Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide in Patients with Moderate-to-Severe HypertensionAn Open-Label, Long-Term Study
    Massimo Volpe
    Cristina Miele
    Uwe Haag
    Clinical Drug Investigation, 2009, 29 : 381 - 391
  • [34] A randomized, double-blind, placebo-controlled. factorial study evaluating the efficacy and safety of co-administration of amlodipine besylate plus olmesartan medoxomil compared to monotherapy in patients with mild to severe hypertension
    Chrysant, S. G.
    Melino, M.
    Karki, S.
    Lee, J.
    Heyrman, R.
    JOURNAL OF HYPERTENSION, 2008, 26 : S376 - S376
  • [35] ADDING HYDROCHLOROTHIAZIDE PROVIDES DOSE-DEPENDENT SEATED BLOOD PRESSURE REDUCTIONS IN PATIENTS WITH MODERATE-TO-SEVERE HYPERTENSION NOT CONTROLLED BY OLMESARTAN MEDOXOMIL 40MG
    Rump, L.
    Sellin, L.
    Ammentorp, B.
    Schmitt, J.
    Laeis, P.
    JOURNAL OF HYPERTENSION, 2010, 28 : E109 - E110
  • [36] Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)
    Warren, Richard B.
    de Bruin-Weller, Marjolein
    Tsianakas, Athanasios
    Khemis, Abdallah
    Szepietowski, Jacek C.
    Hong, H. Chih-Ho
    Armengol, Clara
    Falques, Meritxell
    Agell, Helena
    Massana, Eric
    Gil, Esther Garcia
    Weidinger, Stephan
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
1234